On June 13, 2022, Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, announced that the Japan UPSC UENO Patent Office has issued a patent, No. 7075594, to Aruna Bio and the University of Georgia Research Foundation allowing broad claims on the composition of neural exosomes and their use as a therapeutic for neurological diseases and disorders. The Japanese patent further strengthens Aruna Bio's position in the global exosome and CNS therapeutics arena and enables the company to aggressively advance its proprietary NEUR-Ex™ therapeutic development in the world's second largest and rapidly growing pharmaceutical market. "The potential breadth of CNS patient populations this technology could benefit is vast," said Stephen From, Aruna Bio CEO. "Japan and the US are facing disease-treatment challenges as our populations age. Aruna Bio intends to address this growing therapeutic challenge in 2023 when we anticipate filing an IND application with the US FDA to investigate the safety of neural exosomes in ischemic stroke. And, given our in-house GMP manufacturing capabilities this gives us the ability to move forward rapidly in other disease areas as well." added From.